The next step from high-flux dialysis: application of sorbent technology.
The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove beta(2)-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.
Winchester
James F
JF
RenalTech International, New York, NY 10021, USA. jamesw@renaltech.com
Ronco
Claudio
C
Brady
James A
JA
Cowgill
Larry D
LD
Salsberg
Jamie
J
Yousha
Eric
E
Choquette
Mike
M
Albright
Robert
R
Clemmer
Jonathan
J
Davankov
Vadim
V
Tsyurupa
Maria
M
Pavlova
Ludmila
L
Pavlov
Mikhail
M
Cohen
Gerald
G
Hörl
Walter
W
Gotch
Frank
F
Levin
Nathan W
NW
D000327:Adsorption; D000818:Animals; D006464:Hemoperfusion / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D006801:Humans; D017582:Renal Replacement Therapy / Q000379:methods; D012117:Resins, Synthetic / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000097:blood
D012117:Resins, Synthetic; D001613:beta 2-Microglobulin